Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements - Additional Information (Detail)

v3.19.1
Collaboration and License Agreements - Additional Information (Detail)
1 Months Ended 3 Months Ended
Jun. 30, 2010
Agreement
Jun. 30, 2006
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Janssen Pharmaceutical NV [Member]        
gaap:Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Royalty payment     $ 0 $ 0
Accrued royalties     0 0
Janssen Pharmaceutical NV [Member] | Maximum [Member]        
gaap:Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Percentage of royalty on net sales   8.00%    
Janssen Pharmaceuticals, Inc. [Member]        
gaap:Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Number of development and license agreements | Agreement 2      
DiaTex, Inc. [Member]        
gaap:Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Royalty payment     0 0
Development payment     $ 0 $ 0